However, CTLA-4 inhibitors act predominantly by enhancing the binding affinity between CD28 on T cells and B7-1/B7-2 on antigen-presenting cells (APCs), indirectly augmenting T cell anti-tumor activity [19, 20]. Here, CD86 is linked to neoplasm.